The test is intended for adults 55 and older in the United States who are showing signs or symptoms of cognitive decline.
The FDA has cleared Roche's Elecsys pTau181 test, a blood-based biomarker test for Alzheimer's disease, allowing for earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback